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Abstract
Mycobacterium tuberculosis (Mtb) is a successful pathogen that overcomes the numerous challenges presented
by the immune system of the host. Increasing resistance to the currently available drugs has been a pressing force
for the search for new anti–TB drugs which are active against drug–resistant strains. Also, any new inhibitor
should be active against both the acute and chronic growth phases of the mycobacteria. Methionine S–
adenosyltransferase (MAT) is an enzyme involved in the synthesis of S–adenosylmethionine, a methyl donor
essential for mycolipid and polyamine biosynthesis (during active growth) and for methylation and 
cyclopropylation of mycolipids (necessary for survival during the dormant phase). Inhibitors of the MAT
enzyme appear to be promising anti–TB agents. The homology models of MAT from M. smegmatis (non–
virulent) and M. tuberculosis (pathogenic form) were built using comparative protein modeling principles. 
Docking studies (with the program GOLD) in conjunction with different scoring functions (GoldScore,
ChemScore and HINT score) were employed to explore the binding modes of some known inhibitors of Msm–
MAT and to decipher the crucial interactions between the inhibitors and the enzyme. Various terms of the
scoring functions were correlated to the inhibition data. The docking and scoring protocol established and 
validated for Msm–MAT can be used to search small–molecule 3D databases to extract novel ligands for Mtb–
MAT (pathogenic form). Further, new molecules were designed for Mtb–MAT using the de novo ligand design
approach of the program Ludi.
Keywords. Methionine S–adenosyltransferase (MAT); docking; HINT; GoldScore; ChemScore; de novo
inhibitor design.
1 INTRODUCTION 
Mycobacterium tuberculosis is a pathogen that successfully overcomes the numerous challenges 
presented by the immune system of the host [1]. In 1993, the World Health Organization (WHO)
declared tuberculosis (TB) as a “global emergency” on account of its pathogenic synergy with 
# The work has been presented at the 10th ISCB International Conference on Drug Discovery: Perspectives and
Challenges (Including Symposium on Infectious Diseases) jointly organized by the Indian Society of Chemists and 
Biologists (ISCB), India and the University of Toronto, Canada during 24th–26th February, 2006 at the Central Drug 
Research Institute (CDRI), Lucknow, India. 
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human immunodeficiency virus (HIV) infection. An HIV infection significantly increases the risk 
that new or latent TB infection will progress to the active stage [2,3]. The problem of increasing 
drug–resistance has been a pressing force to develop new anti–TB drugs. There is thus a vital need 
for the identification and development of novel chemotherapeutic compounds active against both 
the acute and the chronic growth phases of the mycobacterium. Focusing on the existing 
antitubercular targets for drug development [4] may be of limited value because chances of 
resistance by mutation in the protein target may render the drugs ineffective. Precisely, because of 
this observed drug–resistance by the bacterium, it is imperative to develop smart new drugs that 
inhibit novel targets that are structurally and functionally different from those currently known. 
Methionine S–adenosyltransferase (MAT) is a cytosolic enzyme that utilizes L–methionine and 
ATP as substrates to synthesize S–adenosylmethionine (SAM), a methyl donor essential for 
mycolipid biosynthesis [5–9]. It has a crucial role in polyamine biosynthesis [10], which occurs 
during active growth, and in the methylation [11] and cyclopropylation of mycolipids that are 
necessary for survival during the chronic (dormant) phase. Because of this, MAT has been 
categorized as an essential enzyme, and is a druggable target for development of new antitubercular 
drugs. This has been corroborated by the study of Berger et al. [12], where they characterized the 
MAT enzyme from M. smegmatis (Msm) and M. tuberculosis (Mtb) and simultaneously validated 
MAT as an anti–mycobacterial target, by inhibiting its activity with some nonselective methionine
and purine analogs. The MAT enzymes from Msm and Mtb are highly homologous (88 % sequence 
identity with identity matrix, Insight II) and conserve 100% sequence similarity in their active sites. 
We report here a study involving docking and ranking of known inhibitors of Msm–MAT in the 
active site of a homology model of Msm–MAT, to establish a protocol that could be applied in 
virtual screening of databases to uncover novel inhibitors for Mtb–MAT. Since the sequences of 
Msm– and Mtb–MAT [13] are highly conserved, we expect the protocol to be successful with Mtb–
MAT. Further, we have used the homology model to design some novel molecules with the 
structure–based drug design program Ludi. 
2 COMPUTATIONAL METHODS
All computations and molecular modeling of the MAT enzyme and its inhibitors were carried 
out on a Pentium IV PC using the programs Insight II (v 2005; Accelrys Inc., USA) and Sybyl (v 
7.1, Tripos Inc., USA) working under the Linux Red Hat Enterprise WS (v 2.1) OS, and GOLD (v 
3.0.1; Cambridge Crystallographic Data Center, UK) [14–16] running under the Windows
environment.
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2.1 Protein and Ligand Preparation
The Msm–MAT enzyme was modeled by comparative protein modeling principles following the 
same protocol as described for Mtb–MAT [13]. Mtb– and Msm–MAT share ~60% sequence 
identity with MAT of E. coli. The sequence alignment that was used to define structurally 
conserved regions (SCRs) is shown in Figure 1. 
Ecol  01:    AKHLFTSESVSEGHPDKIADQISDAVLDAILEQDPKARVACETYVKT
Mtb   01: MSEKGRLFTSESVTEGHPDKICDAISDSVLDALLAADPRSRVAVETLVTT
Msm   01: MS-KGRLFTSESVTEGHPDKICDAISDSVLDALLEQDPKSRVAVETLVTT
          **    ******* ******* * *** ******  **   ** **   * 
Ecol  48: GMVLVGGEITTSAWVDIEEITRNTVREIGYVHS---DMGFDANSCAVLSA 
Mtb   51: GQVHVVGEVTTSAKEAFADITNTVRARILEIGYDSSDKGFDGATCGVNIG 
Msm   50: GQVHVAGEVTTTAY---ADIPKIVRDRILDIGYDSSTKGFDGASCGVNVA 
          * * * ** *  *      *       *         ****   * *
Ecol 095: IGKQSPDI-------|------RADPLE-QGAGDQGLMFGYATNETDVLM
Mtb  101: IGAQSPDIAQGVDTAHEARVEGAADPLDSQGAGDQGLMFGYAINATPELM
Msm  097: IGAQSPDIAQGVDTAHETRVEGKADPLDLQGAGDQGLMFGYAIGDTPELM
          ** *****               ****  *************   *  ** 
Ecol 135: PAPITYAHRLVQRQAEVRKNGTLPWLRPDAKSQVTFQY--DDGKIV--GI
Mtb  151: PLPIALAHRLSRRLTEVRKNGVLPYLRPDGKTQVTIAY--EDNVPV--RL
Msm  147: PLPIALAHRLARRLTEVRKNGVLDYLRPDGKTQVTIQY--DGTTPV--RL
     * **  ****  *  ********  **** * ***  *       *
Ecol 181: DAVVLSTQHSEEIDQKSLQEAVMEEIIKPILPA-----EWLTSATKFFIN 
Mtb  197: DTVVISTQHAADIDLEKTLDPDIREKVLNTVLDDLAHETLDASTVRVLVN 
Msm  193: DTVVLSTQHADGIDLEGTLTPDIREKVVNTVLADLGHETLDTSDYRLLVN 
     * ** ****   **          *                 *      * 
Ecol 226: PTGRFVIGGPMGDCGLTGRKIIVDTYGGMARHGGGAFSGKDPSKVDRSAA
Mtb  247: PTGKFVLGGPMGDAGLTGRKIIVDTYGGWARHGGGAFSGKDPSKVDRSAA
Msm  243: PTGKFVLGGPMGDAGLTGRKIIVDTYGGWARHGGGAFSGKDPSKVDRSAA
          *** ********* ************** ********************* 
Ecol 276: YAARYVAKNIVAAGLADRCEIQVSYAIGVAEPTSIMVETFGTEKVPSEQL 
Mtb  297: YAMRWVAKNVVAAGLAERVEVQVAYAIGKAAPVGLFVETFGTETEDPVKI 
Msm  293: YAMRWVAKNVVAAGLAERVEVQVAYAIGKAAPVGLFVETFGSETVDPAKI 
          ** * **** ****** * * ** **** * *    ***** *      * 
Ecol 326: TLLVREFFDLRPYGLIQMLDLLHPIYKETAAYGHFGREHF--PWEKTDKA 
Mtb  347: EKAIGEVFDLRPGAIIRDLNLLRPIYAPTAAYGHFGRTDVELPWEQLDKV 
Msm  343: EKAIGEVFDLRPAAIVRDLDLLRPIYAPTAAYGHFGRTDIELPWEQTNKV 
               * *****      * ** ***  *********     ***   * 
Figure 1. Sequence alignment of MAT enzymes from E. coli (Ecol), M. tuberculosis (Mtb), and M. smegmatis (Msm)
based on secondary structure and sequence homology. The identical residues in all aligned sequences are indicated with
an asterisk (*), whereas, active site residues colored magenta indicate methionine binding site, blue ATP binding site,
and red phosphate binding residues. The active site “mobile loop” residues are colored green (Mtb: 107–129, Msm:
103–125) and the corresponding residues of Ecol (101–108) which are missing in the crystal structures are indicated by
“-|-”.
The loop regions were modeled using de novo loop generate algorithm or by searching the PDB 
database (by loop search method). Side chain conformations were searched using the Auto Rotamer
Search and the splice regions were optimized by an energy minimization protocol using the 
consistent valence forcefield (CVFF) [17] as implemented in the Discover program (v 2005L, 
Accelrys Inc., USA) with steepest descents and conjugate gradients methods to a convergence 
criterion of 0.001 kcal/mole/Å as the maximum derivative, followed by simulated annealing. The 
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three major regions, N– and C– terminal ends and “active site mobile loop” were further optimized
using an initial minimization step (steepest descents 20,000 steps; conjugate gradients 10,000 
steps), followed by simulated annealing (SA) wherein all degrees of freedom for these three regions 
were allowed to relax, but the heavy atoms of all other residues were held rigid. 
The protocol used for SA involved a slow heating to 600 K in steps of 100 K, followed by a slow 
cooling to 300 K, for a period of 25 picoseconds at every temperature. The lowest energy structure 
from the 300 K trajectory was then subjected to a final round of minimization, with all heavy atoms
tethered by a force constant of 100 kcal/mole/Å2. The minimization was carried out with 10,000 
steps each of steepest descents and conjugate gradients. Finally, the optimized model was checked 
for the bond lengths, bond angles, torsions and chirality of the CD atoms using the ProStat module.
The accuracy and validity of the model was tested with Profiles–3D (Accelrys Inc., USA) [18], 
which calculates a 3D to 1D compatibility score, and graphically portrays the properly folded and 
misfolded region(s) in the protein structure by performing an Eisenberg analysis [19,20] of the 
model.
For compatibility with the GOLD program, Sybyl atom and bond types were assigned to the 
protein atoms. For meaningful results with the GOLD program, it was found necessary to consider 
the Mg2+ ion and this was placed in the homology models by superimposing Asp175, Phe247 and 
Asp255 (the residue numbering refers to Msm–MAT sequence throughout the article, unless 
otherwise specified) over corresponding residues in the X–ray structure of E. coli (PDB code 
1MXB) [5,6], such that the distances of the carboxylate oxygens from the Mg2+ atom were set
between 2.0 and 2.2 Å. Compatibility in the Sybyl HINT program necessitated modification of the 
N– and C–terminal residues as described in the Sybyl HINT manual. The MAT inhibitors (Table 1) 
reported in the literature [12] were sketched in Sybyl, the atom and bond types were assigned, and 
all possible tautomeric states were considered. All ligands were geometry optimized to the gradient 
of 0.001 kcal/mol/Å using the MMFF94 force field. 
2.2 Docking Protocol
GOLD (Genetic Optimization for Ligand Docking) is a genetic algorithm (GA) for docking 
flexible ligands into protein binding sites while considering partial protein flexibility. It uses a 
genetic algorithm to generate and dock the best conformations of a ligand. Residues in a 10 Å 
radius from the Mg2+ ion (which is coordinated to the carboxylate group of Asp179 and also with 
one of the carboxylate oxygens of Asp259) were defined as the active site for the docking study. 
The program was set to terminate when ten solutions within an rmsd of 1.5 Å were identified. The 
options such as flip ring corners, flip amide bonds, flip pyramidal nitrogen were activated, while 
unionized carboxylates were allowed to rotate so as to form favorable H–bonds. Docking was 
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carried out with the default GA settings and the number of GA runs was set to 30. The ten best 
poses for every ligand were stored for post–docking analysis. The two fitness functions – 
GoldScore [21] and ChemScore [21–23] – accessible through the GOLD program were selected for 
scoring the docking poses. 
Table 1. Inhibitors of Msm–MAT with Their % Inhibition Data
Mol ID Chemical Name % Inhibitiona
Methionine analogs
M1 Cycloleucine 25.8r5.1
M2 Methioninamide 23.9r4.8
M3 Ethionine 20.4r4.1
M4 D–Methyl methionine 18.8r3.7
M5 Methylthiopropanaldehyde 18.4r3.7
M6 Methionine, methyl ester 17.7r3.5
M7 Penicillamine 15.0r3.0
M8 L–Methionine sulfoximine 12.6r2.5
M9 Methionine sulfone 9.2r1.8
M10 Methionine sulfoxide 4.0r0.8
Purine analogs
P1 6–Methylpurine 0.0r0.0
P2 2–Aminopurine 11.0r2.1
P3 6–Benzyloxy–purine 17.7r3.4
P4 2–Amino–6–chloropurine–9–acetic acid 23.5r8.4
P5 6–Cyanopurine 24.2r4.6
P6 6–Propoxypurine 27.9r4.0
P7 6–Dimethyl aminopurine 28.0r5.3
P8 2,6–Diaminopurine 29.3r7.9
P9 6–Chloropurine 31.4r7.3
P10 6–Bromopurine 31.4r1.5
P11 2–Amino–6–carboxyethyl–mercaptopurine 31.9r9.8
P12 2–Hydroxypurine 33.8r0.6
P13 2,6–Dichloropurine 35.5r6.9
P14 8–Aza–2,6–diaminopurine 40.0r2.2
P15 6–Mercaptopurine 40.1r2.3
P16 O–Methylguanine 60.3r5.3
P17 Azathioprine 75.5r5.4
P18 8–Azaguanine 81.7r2.8
Uric acid and xanthine analogs
U1 1,3,7–Trimethyluric acid 0.0r0.0
U2 7–Methyluric acid 11.4r2.2
U3 3,7–Dimethyluric acid 27.9r1.6
U4 1–Methyluric acid 43.4r2.9
U5 Uric acid 45.6r11.9
X1 8–Chlorotheophylline 7.0r4.1
X2 Xanthine 35.4r2.5
X3 1–Methylxanthine 35.9r5.8
X4 7–Methylxanthine 36.3r4.2
a per cent (%) inhibition of MAT enzyme at 10 mM inhibitor concentration [Ref. 12]
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2.3 Rescoring using HINT
The best poses ranked by ChemScore for each ligand were taken for Hydropathic INTeraction
(HINT) [24,25] analysis. The protein was corrected to be recognized during HINT calculations as 
described in the Sybyl HINT user manual. The ‘calculate’ and ‘dictionary’ methods as implemented
in Sybyl HINT were employed for partitioning ligand molecules and protein molecule respectively. 
The receptor area covered by the respective ligand pose was considered for calculating the 
intermolecular HINT interaction score. The HINT intermolecular scores were calculated using the 
polar and hydrophobic functions separately as well as in combination.
2.4 Rescoring using HINT
The active site of Mtb–MAT comprising residues in a 10 Å radius from the carboxylate carbon 
atom of Asp179 as the centre was considered in Ludi [26] (accessible through Insight II). Ludi was 
run in the ‘standard mode’ using the Ludi CAP2002 library (presently comprising approximately
78,000 fragments). Conformational search of the fragments was done considering two rotatable 
bonds simultaneously. The remaining parameters were considered at their default settings. The Ludi
scoring functions [27–33] (Energy Estimate 1, 2 and 3) as implemented in InsightII Ludi were 
considered to prioritize the hits from the Ludi CAP database. 
3 RESULTS AND DISCUSSION 
In the post–genomic phase, the exploitation of new biochemical pathways in pathogenic 
microorganisms for development of prophylactic and therapeutic interventions is an attractive 
alternative to antibiotics. The 3D structural information of targets is useful in the drug discovery 
program, as it provides an understanding of the binding interactions at the molecular level. 
Determination of the structures of all the therapeutically important proteins by experimental
methods puts a strain on present day techniques (high–throughput X–ray crystallography or nD–
NMR) and the use of theoretical methods of structure generation (such as homology or comparative
protein modeling) has proven useful in the structure based drug design studies including docking 
and scoring during early phase of drug discovery [34–38]. 
The ligand–receptor binding is a complicated process that poses a challenge to the correct 
theoretical prediction of the binding of a ligand to its receptor. The prediction of the correct binding 
pose is possible with most docking programs. However, the success of a docking method is 
critically dependent on the accuracy of the scoring function that is employed to score these poses 
(ranking). Further, among the available docking programs some do well with certain protein 
families and fail with others. Therefore, it is necessary in docking studies to use a variety of 
docking programs with multiple scoring functions to find the one most suitable for the target under 
investigation. The development of fast and accurate scoring functions is an intensive area of 
156
BioChem Press http://www.biochempress.com
S. A. Khedkar, A. K. Malde, and E. C. Coutinho
Internet Electronic Journal of Molecular Design 2007, 6, 151–166 
research these days. As an alternative, to overcome the limitations of the individual scoring 
function, a Consensus Scoring strategy in which the docked poses are evaluated using different and 
independently developed scoring functions is often used. The use of multiple scoring functions is 
advantageous; since each scoring function is developed independently, its application in ranking the 
ligand poses is similar to repeated sampling. Further, different methods will often agree more on the 
ranking of the actives than on the inactives, and thus together they strengthen the confidence of the 
evaluator that the results are not by chance. In this study, we have used the scoring functions 
accessible through GOLD (GoldScore and ChemScore) that have been tested on a large number of 
complexes extracted from the Protein Data Bank (PDB) and found to be accurate in 70–80% of the 
cases. In addition, we have used the HINT scoring function that is reported to be a good indicator of 
biological activity, to re–rank the poses produced with the program GOLD. 
Msm–MAT has a Mg2+ ion which is coordinateed to the two carboxylate oxygens of Asp175 
(Asp179 in Mtb) and plays a crucial role in the activity of this enzyme. In its recent version, GOLD 
has been programmed to handle metal ions with a defined coordination geometry. In GOLD, the 
interaction of a ligand with a metal atom is treated as "pseudo hydrogen bonding" i.e. GOLD does 
not consider the interaction between the ligand and the metal atom as a coordinate bond. Dummy
atoms are added to the metal atom, which are ‘fitting points’ used to guide the docking process. 
Any interaction of the ligand with these ‘fitting points’ will be scored accordingly within the 
S(hb_ext) part of the GOLD scoring function. Further, GOLD handles protein flexibility in a 
limited way – only the conformations of OH groups of Ser and Thr are adjusted so as to form strong 
H–bonds with the ligand. 
3.1 MAT Active Site
Even though the active site of MAT is located in a large cavity at the dimer interface, the 
methionine (and also the inhibitor) binding site is essentially formed by the residues of one 
monomer; the residues of the other monomer make up the ATP and phosphate binding sites. X–ray 
crystallographic studies have shown that methionine analogs bind at the methionine (i.e. substrate) 
binding site [5–9]. Therefore, in the present study, only the substrate binding site (residues within a 
10Å radius from the Mg+2 ion) was considered for docking studies. The active sites of MAT 
enzyme of Msm and Mtb are almost identical, except for the two mutations: Asp203 and Gly204 in 
Msm to Ala207 and Asp208 in Mtb, respectively. However, these residues are ~10 Å away from the 
center (Mg+2 ion) of the active site. The residues His16, Lys177, Asp175, Ser198, Thr244, Phe247, 
Leu249 and Asp255 (numbering refers to Msm–MAT sequence) are conserved in both the 
mycobacterial species and form the core of the MAT active site. The site–directed mutagenesis
studies, carried out for MAT enzyme from rat, have led to the conclusion that Phe247 (Phe251 in 
Mtb), Asp175 (Asp179 in Mtb), and Lys177 (Lys181 in Mtb) are critical for SAM synthesis, either 
by binding to methionine or possibly by being involved in the subsequent steps of the mechanism
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[8,9]. These conclusions were based on the fact that their mutations resulted in an absolute loss of 
MAT activity when compared to the native enzyme.
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Figure 2. The correlation of ChemScore with the % inhibition of Msm MAT by: (A) methionine analogs (correlation
statistics: Pearson R = 0.69, Spearman rho = 0.76, P = 0.028, Kendall’s tau = 0.57, P= 0.048, correlation is significant
at the 0.05 level), (B) purine analogs (correlation statistics: Pearson R = 0.64; Spearman rho = 0.47, P = 0.49; Kendall’s
tau = 0.33, P = 0.05, correlation is significant at the 0.05 level ), and (C) uric acid and xanthine analogs (correlation
statistics: Pearson R = 0.92; Spearman rho = 0.92, P = 0.001; Kendall’s tau = 0.78, P = 0.05; correlation is significant
at the 0.05 level ). Refer text for details.
3.2 Post–Docking Analysis
As mentioned earlier, three scoring functions, GoldScore, ChemScore and HINT score, were 
employed for docking and/or re–scoring of the docked poses. The statistical parameters such as 
Pearson R (referred henceforth to as R), Spearman rho, Kendall’s tau were calculated to relate the 
scores with the experimental activity data. In the present case, the activity of MAT inhibitors has 
been reported as per cent (%) inhibition of MAT enzyme at 10 mM inhibitor concentration. It is 
seen that ChemScore correlates well with the experimental activity of the Msm–MAT inhibitors. 
The rescoring of these poses with HINT reassures the correlation; an improved correlation statistics 
for HINT over ChemScore is achieved. The plots of ChemScore and HINT score of docked 
compounds against experimental data are shown in Figures 2 and 3 respectively. The biological 
activity of the methionine series of inhibitors shows a correlation (R) of 0.69 and 0.85 with 
ChemScore and HINT score, respectively. The ‘metal interaction’ and ‘lipophilic’ terms have major
accounts in the ChemScore (with R of 0.86 and 0.67, respectively) of the inhibitors. In HINT scores 
(which is the sum of polar and hydrophobic interactions) the affinity correlates strongly with polar 
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interactions (R = 0.84). 
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Figure 3. The correlation of HINT Score with the % inhibition of Msm MAT by: (A) methionine analogs (correlation
statistics: Pearson R = 0.85, Spearman rho = 0.85, P = 0.004, Kendall’s tau = 0.72, P= 0.007, correlation is significant
at the 0.05 level), (B) purine analogs (correlation statistics: Pearson R = 0.65; Spearman rho = 0.45, P = 0.07; Kendall’s
tau = 0.33, P = 0.064, correlation is significant at the 0.05 level ), and (C) uric acid and xanthine analogs (correlation
statistics: Pearson R = 0.53; Spearman rho = 0.72, P = 0.019; Kendall’s tau = 0.51, P = 0.04; correlation is significant
at the 0.05 level ). Refer text for details.
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Figure 4. Correlation of ChemScore (A) and HINT score (B) with % inhibition by representative molecules (molecules
M1, X4, U5, P16, P17, P18 in Table 1) from each inhibitor class. 
The correlation of percent Msm–MAT inhibition by purine analogs with ChemScore and HINT
score exhibit Pearson R of 0.64 and 0.65 respectively. In HINT score, the polar component has a 
major contribution (R = 0.64). The correlation between the score and activity (% inhibition) for this 
class is sufficiently good to discriminate between the active and inactive compounds. The 
correlation statistics is seen to improve (R = 0.74) when low active compounds (with MAT 
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inhibition less than 25%) were neglected in the analysis. 
The activity of xanthine and uric acid analogs shows a better correlation with ChemScore (R = 
0.92) than with HINT score (R = 0.75). Figure 4 shows that both ChemScore and HINT scores are 
able to discriminate molecules of different chemical classes as active, moderately active and poorly 
active.
M1 P15
P16 P17
Figure 5. Pictorial views of the most potent inhibitors, cycloleucine (M1), 6–Mercaptopurine (P15), O–Methylguanine
(P16), azathioprine (P17), 8–azaguanine (P18), Uric acid (U5) and 7–Methylxanthine (X4) in the Msm–MAT active
site obtained through docking.
A docking study of the Msm–MAT inhibitors in the active site of the Mtb–MAT model reveals 
the same pattern of binding configurations and predicted affinities (ChemScores); this is not 
surprising as the active site of the MAT enzyme from Msm and Mtb are highly conserved. From
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this analysis, it is clear that ChemScore can be confidently employed here as a scoring function for 
docking small organic molecules in 3D–databases. Even though the HINT score performs better 
than ChemScore, in that it is well able to discriminate actives from inactives, its value as a scoring 
function in docking is limited. However, it can be used to more accurately rank a small set of MAT 
inhibitors that have been filtered based on the ChemScore.
P18 U5
X4
Figure 5. (Continued)
The enzyme–inhibitor complexes (Figure 5) were visually analyzed with the Silver interface of 
the program GOLD. The interactions between the inhibitors and the active site residues in Msm–
MAT are described below. 
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2.4 Å; see M1 in Figure 5). The aliphatic side chains of the inhibitors are stabilized through 
hydrophobic interactions with the phenyl ring of Phe247 (Phe251 in Mtb). The aromatic rings of 
purine, uric acid and xanthine analogs participate in a Sstacking interaction with the phenyl ring of 
Phe247 (Phe251 in Mtb). Phe247 has been reported to exert a crucial role in the activity of the 
MAT enzyme [8,9], and it is not surprising that this residue enters into several crucial interactions 
with the inhibitors. In addition, several important interactions between the Mg2+ ion and the 
electronegative atoms in the inhibitors are seen. In majority of the purine analogs, this occurs 
through the sp2 hybridized N3 atom (for example, molecules P1, P2, P5, P9, P10, P13, P15, P16 in 
Table 1) or the N7 atom (molecules P3, P6, P8, P14, P18, X01, X2, X3 in Table 1). In addition, the 
N7 atom of some of the inhibitors is also involved in a hydrogen bond with Lys177 (Lys181 in 
Mtb; molecules P1, P4, P9, P10, P12, P15 in Table 1) and with Ser198 (Ser202 in Mtb; molecules
P11, P17 in Table 1). In cases where the N7 atom is substitued, such as the uric acid analogs U2
and U3 (Table 1), the carbonyl oxygen at C8 coordinates with the Mg+2 ion while the N1 atom
forms a hydrogen bond with Thr244. In molecules with no substitution at N7 and N9 atoms
(molecules U4, U5 in Table 1), the C8 carbonyl oxygen forms a hydrogen bond with Thr244. The 
molecule P16 does not coordinate with the Mg+2 ion. Azathioprine (molecule P17 in Table 1) is one 
of the molecules with high activity and forms hydrogen bonds with Lys177 through the N3 atom
and with Ser198 through the N7 atom; the Mg2+ ion is stabilized by coordination to the oxygen of 
the nitro group. The most active inhibitor known for Msm–MAT, 8–azaguanine (molecule P18 in 
Table 1) forms a hydrogen bond with Lys177 through the 6–carbonyl oxygen and the Mg2+ ion is 
coordinated with its N7 and N8 atoms.
In conclusion, it can be said that while hydrogen bonds with Lys177, Ser198 and Asp255, and 
hydrophobic/Sstacking interactions with Phe247 are important for strong binding, coordination 
with Mg2+ ion is a minimum requirement for inhibition of the MAT enzyme. A combination of 
these features can be used as a query in a database search. 
3.3 Design of Novel MAT Inhibitors
The design of new and selective inhibitors of an enzyme is one of the most important
applications in contemporary rational drug design. When information on the binding site of the 
target protein is available, novel inhibitors can be designed from scratch using de novo approaches. 
As a de novo design tool, Ludi first generates the interaction sites using a set of rules that are 
intended to cover the complete range of energetically favorable orientations for hydrogen bonds and 
hydrophobic contacts. Then using the fragment approach, Ludi positions small fragments in the 
clefts of the protein structure (i.e., active site) such that hydrogen bonds can be formed with 
acceptor/donor groups, and hydrophobic pockets are filled with hydrophobic groups. A fragment is 
chosen for its potential to have good hydrophobic and hydrogen bonding interactions with the target 
receptor. The molecular fragments placed in the active site are then linked together to form a 
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molecule that can fit into the cavity of the protein under study. 
Table 2. Some inhibitors of Mtb–MAT designed using de novo approach of Ludi.
Sr. No. Structure Ludi Score Predicted Ki(micro molar)
1
NH2
579 1.58
2
N
H
NH2
CH3
CH3
551 3.16
3
NH
HN CH
H3C
H3C
3
415 63.1
4 HN
O
391 100
5 N
H
S CN
O
C(CH3)3
378 158.5
The structures of novel inhibitors suggested with this approach are shown in Table 2, along with 
their Ludi scores and predicted binding affinities (Ki). Among the scoring functions accessible 
through Ludi for prioritizing fragment hits, Energy Estimate 2 was used for de novo design of MAT 
inhibitors. This scoring function estimates the change in free energy upon binding of the fragment
to the receptor, and the score correlates with the dissociation constant, Ki. Each fragment is 
evaluated as a function of the potential number of hydrogen bonds, hydrophobic and ionic contacts, 
and a penalty towards the freezing of the internal degrees of freedom of the ligand. A few inhibitors 
(Table 2) with high scores are predicted with dissociation constant (Ki) values in the mM to µM 
range (corresponding to Ludi ‘Energy Estimate 2’ scores in the range 300 to 600). The designed 
molecules bear the properties of lead–like molecules (rule–of–three) [39] with MW below 300, 
number of H–bond donors/acceptors less than 3 and logP less than 3, so that after lead optimization,
the drug–like molecules will fulfill Lipinski’s rule–of–five [40]. These moieties offer a basic lead 
structure for recognition with MAT active site and could be further optimized for potency and 
selectivity.
4 CONCLUSIONS 
The homology models have been used in the absence of any experimental structures of Msm and 
Mtb–MAT to understand the binding modes of known inhibitors via a docking and scoring 
protocol. A consensus scoring strategy seems best suited for the problem at hand. Though the 
correlation between activities and scores are statistically significant, there is some room for
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improvement. One reason for the lack of a very good correlation of docking scores with the 
inhibition data could be due to the variation (up to r12 %) in the reported percentage (%) inhibition 
data for these inhibitors, which was not considered during the correlation analysis. Our previous 
study [13] on the molecular electrostatic potential of MAT enzyme from Mtb and humans revealed 
that the electrostatic potential covering the active site residues (Asp179, Gly16 and His17) have 
sharply differing values, with the active site of Mtb–MAT being more deeply negative [13]. The 
pattern of the MEP in the two MATs (mycobacterium and human) indicates that the two proteins 
would bind inhibitors in the same relative sense, but the binding affinities of a given inhibitor will 
not be the same for the two proteins, due to the differences in the absolute values of the electrostatic 
potential. Since the MAT proteins from Msm and Mtb are highly conserved, many of the inferences 
derived for Msm–MAT can be confidently extrapolated for Mtb–MAT. This study gives an insight 
into the molecular interactions that play a significant role in the binding affinity of the MAT 
inhibitors. Further, new lead molecules designed using the de novo approach could be developed 
into useful drugs for treatment of tuberculosis.
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